Filgrastim Biosimilars Market - By Application (Oncology, Chronic and Autoimmune Diseases, Blood disorders, Growth hormone deficiency, Others), By Distribution Channel (Hospital pharmacies, Retail pharmacies, Online pharmacies), And By Region, Opportunities And Strategies – Global Filgrastim Biosimilars Market Forecast To 2030

Starting Price : $4000 | Pages : 266 | Published : December 2020 | SKU CODE : o&s196 | Format :

Request Sample

Filgrastim Biosimilars Market Definition

The filgrastim biosimilars market consists of sales of filgrastim biosimilars and related services by entities (organizations, sole traders and partnerships) that manufacture filgrastim biosimilars. Filgrastim biosimilar treatment is used to stimulate the bone marrow to produce more neutrophils (white blood cells) to fight infection in patients undergoing chemotherapy for cancer treatment. The drugs may also be used to increase the number of hematopoietic stem cells in the blood before collection for use in hematopoietic stem cell transplantation.  Filgrastim treatment may also be used for treating other diseases such as chronic and autoimmune diseases, growth hormone deficiency and infectious diseases.

Filgrastim Biosimilars Market Size

The global filgrastim biosimilars market reached a value of nearly $785.33 million in 2019, having increased at a compound annual growth rate (CAGR) of 12.13% since 2015.  The market is expected to grow from $785.33 million in 2019 to $860.12 million in 2023 at a rate of 2.30%. The growth is mainly due to the patent expiration of filgrastim biologics and government initiatives. The market is expected to grow from $860.12 million in 2023 to $984.23 million in 2025 at a CAGR of 6.97%.  The market is expected to grow and reach $1,279.86 million in 2030 with a CAGR of 5.39%.

Growth in the historic period resulted from emerging markets growth, increase in patent expiration, government initiatives, increased healthcare expenditure, low cost of biosimilars, strong pipeline of drugs and increase in biopharmaceutical R&D expenditure. This growth was restricted by low number of drug approvals and lack of awareness on biosimilars among primary care physicians and specialists.

Going forward, aging population, increase in healthcare access,and rising prevalence of chronic diseases are expected to drive the market. Rise of pegfilgrastim, stringent regulations related to biosimilar approvals, prolonged production and approval times and impact of COVID-19 are major factors that could hinder the growth of the filgrastim biosimilars market in the future.

Filgrastim Biosimilars Market Drivers

The key drivers of the filgrastim biosimilars market include:

Aging Population

The population profile of most countries is becoming older, thus driving the demand for biopharmaceuticals such as filgrastim biosimilars to treat the side effects caused by the treatment of various chronic diseases including cancer. The proportion of people above the age of 65 years increased globally and age-related chronic ailments also increased. For example, the percentage of seniors is expected to grow from 28% in 2019 to 38% in 2050 in Japan. The increase in the aging population has expanded the patient pool of many chronic diseases such as cancer. People suffering from these diseases are expected to be more vulnerable to chronic diseases, thus significantly impacting market growth during this period.

Filgrastim Biosimilars Market Restraints

The key restraints on the filgrastim biosimilars market include:

Effect Of COVID-19

The market is expected to be negatively impacted by the COVID-19 situation and its economic implications. With the majority of countries suffering from the impact of COVID-19, many countries are looking for a way to cure COVID-19. The pandemic has had a serious and disruptive effect on oncology clinical trials and treatment, with both immediate and delayed consequences. According to a study conducted by the Cancer Research UK in July 2020, one in three cancer patients have confirmed that their treatment has been impacted by the effects of COVID-19. The short-term effects include staff and resources being reassigned to deal with COVID patients. In the longer term, trials testing treatments for COVID-19 have been prioritized. A sharp reduction in recruitment to ongoing trials and a delay in the planned launch of new oncology studies is expected to negatively impact the market. The market is also expected to be negatively impacted by patients preferring the pegfilgrastim biologic Neulasta due to its option of an on-body injector which allows immunocompromised patients undergoing chemotherapy to skip at least a couple of in-person visits to the infusion center without exposing them to higher risks of neutropenia and infection. Therefore higher demand for the pegfilgrastim biologic exists, thus restraining the growth of the market, as filgrastim biosimilars are only available for administration by syringe at this time and need to be given continuously for 14 days.

Filgrastim Biosimilars Market Trends

Major trends influencing the filgrastim biosimilars market include:

Shift Towards Development Of Biosimilars

Pharmaceutical companies are shifting towards biosimilar drug development. Pharma companies had focused on small molecules for decades, but the rate of innovation in that field has slowed dramatically, leading to the shift towards biosimilars. These research and development (R&D) activities have led to increasing success rates in clinical trials for biosimilars. R&D is being carried out by market leaders in the biosimilars market as they continuously strive to make breakthroughs in the form of new and effective biosimilars. The unmet needs with respect to chronic disease therapies help pharmaceutical companies to innovate and develop biologic molecules. For instance, Amgen and Kirin Holdings Company are developing a filgrastim biosimilar which stimulates the growth of white blood cells to treat neutropenia, a common adverse event in patients receiving chemotherapy for breast cancer. Currently, the drug is in Phase I/II clinical study for breast cancer patients. In June 2020, Pfizer, an American multinational pharmaceutical company, received approval from the US Food and Drug Administration to introduce its biosimilar drug for lowering the incidence of infection as manifested by febrile neutropenia in patients with non-myeloid malignancies receiving myelosuppressive anticancer drugs.

Demand For Biosimilars In The Treatment Of Neutropenia

The demand for filgrastim biosimilars to treat chemotherapy-related neutropenia in cancer patients has been increasing owing to the cost effectiveness of the treatment and equivalent efficiency of the biosimilars to the long-used chemical and biological drugs. For instance, according to a comparative study conducted to understand the cost efficiency of filgrastim biosimilars, it was concluded that prophylaxis or treatment of febrile neutropenia with Zarzio is cost-efficient under all possible treatment scenarios relative to Neupogen and Neulasta. It was seen that the cost of Neupogen treatment ranged from $151 (1 day) to $2114 (14 days), compared to $112 and $1575 for Zarzio, thus yielding potential cost savings from $39 to $540 for the latter.

Opportunities And Recommendations In The Filgrastim Biosimilars Market

Opportunities: The top opportunities in the filgrastim biosimilars market segmented by application will arise in the oncology segment, which will gain $57.5 million of global annual sales by 2023. The top opportunities in the filgrastim biosimilars market segmented by distribution channel will arise in the online pharmacies segment, which will gain $49.1 million of global annual sales by 2023. The filgrastim biosimilars market size will gain the most in the USA at $21.9 million.

Market-trend-based strategies for the filgrastim biosimilars market includes investing extensively in R&D activities for the development of effective and innovative biosimilars, production of biosimilars for neutropenia treatment to improve revenues and increasing their focus on M&A growth strategies. Player-adopted strategies in the filgrastim biosimilars market include investing in expanding operations through innovative product launches, strategic partnerships, acquisitions and mergers to strengthen their service offerings.

Recommendations: To take advantage of the opportunities, the business research company recommends the filgrastim biosimilars market companies to focus on a strategic partnerships, focus on research & development, focus on the production of biosimilars for neutropenia treatment, expand in emerging markets, leverage e-commerce to maximize reach and revenues, leverage online pharmacies, set up authorized distributors and sales representatives, provide competitively priced offerings in low-income countries to reach new users companies, focus on creating awareness, participate in trade shows and events and focus on creating awareness among patients and doctors.

Filgrastim Biosimilars Market Segmentation

The filgrastim biosimilars market is segmented by application, by distribution channel
By Application - The filgrastim biosimilars market can be segmented by application
    • a. Oncology
    • b. Chronic and Autoimmune Diseases
    • c. Blood disorders
    • d. Growth hormone deficiency
    • e. Others
The oncology was the largest segment of the filgrastim biosimilars market by application, accounting for 61.3% of the total market in 2019. Going forward, oncology is expected to be the fastest growing segment in the filgrastim biosimilars market, at a CAGR of 6.0%.

By Distribution Channel -

The filgrastim biosimilars market can be segmented by distribution channel
    • a. Hospital pharmacies
    • b. Retail pharmacies
    • c. Online pharmacies
The hospital pharmacies was the largest segment of the filgrastim biosimilars market by type, accounting for 91.7% of the total market in 2019. Going forward, the retail pharmacies segment is expected to be the fastest growing segment in the filgrastim biosimilars market, at a CAGR of 16.7%.
By Geography- The filgrastim biosimilars market segmented into
    • o North America
      • USA
    • o Western Europe
      • France
      • Germany
      • UK
    • o Asia Pacific
      • Australia
      • China
      • India
      • Indonesia
      • Japan
      • South Korea
    • o South America
      • Brazil
    • o Middle East
    • o Eastern Europe
      • Russia
    • o Africa
Western Europe was the largest region in the global filgrastim biosimilars market, accounting for 47.3% of the total in 2019. It was followed by the North America, Asia Pacific and then the other regions. Going forward, the fastest-growing regions in the filgrastim biosimilars market will be Asia Pacific and Middle East, where growth will be at CAGRs of 15.4% and 14.4% respectively. These will be followed by South America and Eastern Europe, where the markets are expected to register CAGRs of 12.5% and 9.6% respectively.

Filgrastim Biosimilars Competitive Landscape

Major Competitors are:
    • • Teva Pharmaceutical Industries
    • • Novartis International AG
    • • Biocon Limited
    • • Intas Biopharmaceuticals
    • • Dr. Reddy’s Laboratories
Other Competitors include:
    • • Pfizer
    • • Cadila Healthcare Ltd
    • • Abbott Laboratories
    • • Reliance Life Science Pvt. Ltd
    • • Gennova Biopharmaceuticals (Emcure)
    • • Sandoz Pty Ltd
    • • Apotex Pty Ltd
    • • Mylan
    • • Kyowa Kirin Co., Ltd
    • • Gennova Biopharmaceuticals Limited
    • • Lupin Limited
    • • Coherus Biosciences Inc
    • • Cadila Pharmaceutical
    • • Mochida Pharmaceutical
    • • Fuji Pharma
    • • Napp Pharmaceuticals
    • • Coherus BioSciences, Inc.
    • • Fresenius Kabi
    • • Adello Biologics
    • • Apobiologix (Apotex)
    • • Tanvex BioPharma
    • • Eurofarma Laboratórios

    1. Filgrastim Biosimilars Market Executive Summary

    2. Table of Contents

    3. List of Figures

    4. List of Tables

    5. Report Structure

    6. Introduction

    6.1.1. Segmentation By Geography

    6.1.2. Segmentation By Application

    6.1.3. Segmentation By Distribution Channel

    7. Filgrastim Biosimilars Market Characteristics

    7.1. Market Definition

    7.2. Market Segmentation By Application

    7.2.1. Oncology

    7.2.2. Chronic And Autoimmune Diseases

    7.2.3. Blood Disorders

    7.2.4. Growth Hormone Deficiency

    7.2.5. Others

    7.3. Market Segmentation By Distribution Channel

    7.3.1. Hospital Pharmacies

    7.3.2. Retail Pharmacies

    7.3.3. Online Pharmacies

    8. Filgrastim Biosimilars Market Trends And Strategies

    8.1. Shift Towards Development Of Biosimilars

    8.2. Demand For Biosimilars In The Treatment Of Neutropenia

    8.3. Revised FDA Regulations To Facilitate Biosimilar Drug Development

    8.4. Higher Investments

    8.5. Growing Mergers And Acquisitions

    9. COVID-19 Impact On The Filgrastim Biosimilars Market

    10. Global Filgrastim Biosimilars Market Size And Growth

    10.1. Market Size

    10.2. Historic Market Growth, 2015 – 2019, Value ($ Million)

    10.2.1. Drivers Of The Market 2015 – 2019

    10.2.2. Restraints On The Market 2015 – 2019

    10.3. Forecast Market Growth, 2019 – 2023, 2025F, 2030F Value ($ Million)

    10.3.1. Drivers Of The Market 2019 – 2023

    10.3.2. Restraints On The Market 2019 – 2023

    11. Global Filgrastim Biosimilars Market Segmentation

    11.1. Global Filgrastim Biosimilars Market, Segmentation By Application, Historic And Forecast, 2015 – 2019, 2023F, 2025F, 2030F, Value ($ Million)

    11.1.1. Oncology

    11.1.2. Chronic and Autoimmune Diseases

    11.1.3. Blood Disorders

    11.1.4. Others

    11.1.5. Growth Hormone Deficiency

    11.2. Global Filgrastim Biosimilars Market, Segmentation By Distribution Channel, Historic And Forecast, 2015 – 2019, 2023F, 2025F, 2030F, Value ($ Million)

    11.2.1. Hospital Pharmacy

    11.2.2. Retail Pharmacy

    11.2.3. Online Pharmacy

    12. Filgrastim Biosimilars Market, Regional And Country Analysis

    12.1. Global Filgrastim Biosimilars Market, By Region, Historic and Forecast, 2015 – 2019, 2023F, 2025F, 2030F, Value ($ Million)

    12.2. Global Filgrastim Biosimilars Market, By Country, Historic and Forecast, 2015 – 2019, 2023F, 2025F, 2030F, Value ($ Million)

    13. Asia-Pacific Filgrastim Biosimilars Market

    13.1. Asia-Pacific Filgrastim Biosimilars Market Overview

    13.2. Asia Pacific Filgrastim Biosimilars Market Overview

    13.2.1. Region Information

    13.2.2. Impact Of COVID-19

    13.2.3. Market Information

    13.2.4. Background Information

    13.2.5. Government Initiatives

    13.2.6. Regulations

    13.2.7. Regulatory Bodies

    13.2.8. Major Associations

    13.2.9. Corporate Tax Structure

    13.2.10. Investments

    13.2.11. Major Companies

    13.3. Asia-Pacific Filgrastim Biosimilars Market, Historic Market Growth, 2015 – 2019, Value ($ Million)

    13.4. Asia-Pacific Filgrastim Biosimilars Market, Forecast Market Growth, 2019 – 2023, 2025F, 2030F Value ($ Million)

    13.5. Asia-Pacific Filgrastim Biosimilars Market, Segmentation By Application, Historic And Forecast, 2015 – 2019, 2023F, 2025F, 2030F, Value ($ Million)

    13.6. Asia-Pacific Filgrastim Biosimilars Market, Segmentation By Distribution Channel, Historic And Forecast, 2015 – 2019, 2023F, 2025F, 2030F, Value ($ Million)

    13.7. Asia-Pacific Filgrastim Biosimilars Market: Country Analysis

    13.8. China Filgrastim Biosimilars Market

    13.9. China Filgrastim Biosimilars Market Overview

    13.9.1. Country Information

    13.9.2. Impact Of COVID-19

    13.9.3. Market Information

    13.9.4. Background Information

    13.9.5. Government Initiatives

    13.9.6. Regulations

    13.9.7. Regulatory Bodies

    13.9.8. Major Associations

    13.9.9. Corporate Tax Structure

    13.9.10. Investments

    13.9.11. Major Companies

    13.10. China Filgrastim Biosimilars Market, Historic Market Growth, 2015 – 2019, Value ($ Million)

    13.11. China Filgrastim Biosimilars Market, Forecast Market Growth, 2019 – 2023, 2025F, 2030F Value ($ Million)

    13.12. China Filgrastim Biosimilars Market, Segmentation By Application, Historic And Forecast, 2015 – 2019, 2023F, 2025F, 2030F, Value ($ Million)

    13.13. China Filgrastim Biosimilars Market, Segmentation By Distribution Channel, Historic And Forecast, 2015 – 2019, 2023F, 2025F, 2030F, Value ($ Million)

    13.14. India Filgrastim Biosimilars Market

    13.15. India Filgrastim Biosimilars Market Overview

    13.15.1. Country Information

    13.15.2. Impact Of COVID-19

    13.15.3. Market Information

    13.15.4. Background Information

    13.15.5. Government Initiatives

    13.15.6. Regulations

    13.15.7. Regulatory Bodies

    13.15.8. Major Associations

    13.15.9. Corporate Tax Structure

    13.15.10. Investments

    13.15.11. Major Companies

    13.16. India Filgrastim Biosimilars Market, Historic Market Growth, 2015 – 2019, Value ($ Million)

    13.17. India Filgrastim Biosimilars Market, Forecast Market Growth, 2019 – 2023, 2025F, 2030F Value ($ Million)

    13.18. India Filgrastim Biosimilars Market, Segmentation By Application, Historic And Forecast, 2015 – 2019, 2023F, 2025F, 2030F, Value ($ Million)

    13.19. India Filgrastim Biosimilars Market, Segmentation By Distribution Channel, Historic And Forecast, 2015 – 2019, 2023F, 2025F, 2030F, Value ($ Million)

    13.20. Japan Filgrastim Biosimilars Market

    13.21. Japan Filgrastim Biosimilars Market Overview

    13.21.1. Country Information

    13.21.2. Impact Of COVID-19

    13.21.3. Market Information

    13.21.4. Background Information

    13.21.5. Government Initiatives

    13.21.6. Regulations

    13.21.7. Regulatory Bodies

    13.21.8. Major Associations

    13.21.9. Corporate Tax Structure

    13.21.10. Investments

    13.21.11. Major Companies

    13.22. Japan Filgrastim Biosimilars Market, Historic Market Growth, 2015 – 2019, Value ($ Million)

    13.23. Japan Filgrastim Biosimilars Market, Forecast Market Growth, 2019 – 2023, 2025F, 2030F Value ($ Million)

    13.24. Japan Filgrastim Biosimilars Market, Segmentation By Application, Historic And Forecast, 2015 – 2019, 2023F, 2025F, 2030F, Value ($ Million)

    13.25. Japan Filgrastim Biosimilars Market, Segmentation By Distribution Channel, Historic And Forecast, 2015 – 2019, 2023F, 2025F, 2030F, Value ($ Million)

    13.26. Australia Filgrastim Biosimilars Market

    13.27. Australia Filgrastim Biosimilars Market, Historic Market Growth, 2015 – 2019, Value ($ Million)

    13.28. Australia Filgrastim Biosimilars Market, Forecast Market Growth, 2019 – 2023, 2025F, 2030F Value ($ Million)

    13.29. Australia Filgrastim Biosimilars Market, Segmentation By Application, Historic And Forecast, 2015 – 2019, 2023F, 2025F, 2030F, Value ($ Million)

    13.30. Australia Filgrastim Biosimilars Market, Segmentation By Distribution Channel, Historic And Forecast, 2015 – 2019, 2023F, 2025F, 2030F, Value ($ Million)

    13.31. Indonesia Filgrastim Biosimilars Market

    13.32. Indonesia Filgrastim Biosimilars Market, Historic Market Growth, 2015 – 2019, Value ($ Million)

    13.33. Indonesia Filgrastim Biosimilars Market, Forecast Market Growth, 2019 – 2023, 2025F, 2030F Value ($ Million)

    13.34. Indonesia Filgrastim Biosimilars Market, Segmentation By Application, Historic And Forecast, 2015 – 2019, 2023F, 2025F, 2030F, Value ($ Million)

    13.35. Indonesia Filgrastim Biosimilars Market, Segmentation By Distribution Channel, Historic And Forecast, 2015 – 2019, 2023F, 2025F, 2030F, Value ($ Million)

    13.36. South Korea Filgrastim Biosimilars Market

    13.37. South Korea Filgrastim Biosimilars Market, Historic Market Growth, 2015 – 2019, Value ($ Million)

    13.38. South Korea Filgrastim Biosimilars Market, Forecast Market Growth, 2019 – 2023, 2025F, 2030F Value ($ Million)

    13.39. South Korea Filgrastim Biosimilars Market, Segmentation By Application, Historic And Forecast, 2015 – 2019, 2023F, 2025F, 2030F, Value ($ Million)

    13.40. South Korea Filgrastim Biosimilars Market, Segmentation By Distribution Channel, Historic And Forecast, 2015 – 2019, 2023F, 2025F, 2030F, Value ($ Million)

    14. Western Europe Filgrastim Biosimilars Market

    14.1. Western Europe Filgrastim Biosimilars Market Overview

    14.1.1. Region Information

    14.1.2. Impact Of COVID-19

    14.1.3. Market Information

    14.1.4. Background Information

    14.1.5. Government Initiatives

    14.1.6. Regulations

    14.1.7. Regulatory Bodies

    14.1.8. Major Associations

    14.1.9. Taxes Levied

    14.1.10. Corporate Tax Structure

    14.1.11. Investments

    14.1.12. Major Companies

    14.2. Western Europe Filgrastim Biosimilars Market, Historic Market Growth, 2015 – 2019, Value ($ Million)

    14.3. Western Europe Filgrastim Biosimilars Market, Forecast Market Growth, 2019 – 2023, 2025F, 2030F Value ($ Million)

    14.4. Western Europe Filgrastim Biosimilars Market, Segmentation By Application, Historic And Forecast, 2015 – 2019, 2023F, 2025F, 2030F, Value ($ Million)

    14.5. Western Europe Filgrastim Biosimilars Market, Segmentation By Distribution Channel, Historic And Forecast, 2015 – 2019, 2023F, 2025F, 2030F, Value ($ Million)

    14.6. Western Europe Filgrastim Biosimilars Market: Country Analysis

    14.7. UK Filgrastim Biosimilars Market

    14.8. UK Filgrastim Biosimilars Market Overview

    14.8.1. Country Information

    14.8.2. Impact Of COVID-19

    14.8.3. Market Information

    14.8.4. Background Information

    14.8.5. Government Initiatives

    14.8.6. Regulations

    14.8.7. Regulatory Bodies

    14.8.8. Major Associations

    14.8.9. Taxes Levied

    14.8.10. Corporate Tax Structure

    14.8.11. Investments

    14.8.12. Major Companies

    14.9. UK Filgrastim Biosimilars Market, Historic Market Growth, 2015 – 2019, Value ($ Million)

    14.10. UK Filgrastim Biosimilars Market, Forecast Market Growth, 2019 – 2023, 2025F, 2030F Value ($ Million)

    14.11. UK Filgrastim Biosimilars Market, Segmentation By Application, Historic And Forecast, 2015 – 2019, 2023F, 2025F, 2030F, Value ($ Million)

    14.12. UK Filgrastim Biosimilars Market, Segmentation By Distribution Channel, Historic And Forecast, 2015 – 2019, 2023F, 2025F, 2030F, Value ($ Million)

    14.13. Germany Filgrastim Biosimilars Market

    14.14. Germany Filgrastim Biosimilars Market, Historic Market Growth, 2015 – 2019, Value ($ Million)

    14.15. Germany Filgrastim Biosimilars Market, Forecast Market Growth, 2019 – 2023, 2025F, 2030F Value ($ Million)

    14.16. Germany Filgrastim Biosimilars Market, Segmentation By Application, Historic And Forecast, 2015 – 2019, 2023F, 2025F, 2030F, Value ($ Million)

    14.17. Germany Filgrastim Biosimilars Market, Segmentation By Distribution Channel, Historic And Forecast, 2015 – 2019, 2023F, 2025F, 2030F, Value ($ Million)

    14.18. France Filgrastim Biosimilars Market

    14.19. France Filgrastim Biosimilars Market, Historic Market Growth, 2015 – 2019, Value ($ Million)

    14.20. France Filgrastim Biosimilars Market, Forecast Market Growth, 2019 – 2023, 2025F, 2030F Value ($ Million)

    14.21. France Filgrastim Biosimilars Market, Segmentation By Application, Historic And Forecast, 2015 – 2019, 2023F, 2025F, 2030F, Value ($ Million)

    14.22. France Filgrastim Biosimilars Market, Segmentation By Distribution Channel, Historic And Forecast, 2015 – 2019, 2023F, 2025F, 2030F, Value ($ Million)

    15. Eastern Europe Filgrastim Biosimilars Market

    15.1. Eastern Europe Filgrastim Biosimilars Market Overview

    15.1.1. Region Information

    15.1.2. Impact Of COVID-19

    15.1.3. Market Information

    15.1.4. Background Information

    15.1.5. Government Initiatives

    15.1.6. Regulations

    15.1.7. Regulatory Bodies

    15.1.8. Major Associations

    15.1.9. Taxes Levied

    15.1.10. Corporate Tax Structure

    15.1.11. Investments

    15.1.12. Major Companies

    15.2. Eastern Europe Filgrastim Biosimilars Market, Historic Market Growth, 2015 – 2019, Value ($ Million)

    15.3. Eastern Europe Filgrastim Biosimilars Market, Forecast Market Growth, 2019 – 2023, 2025F, 2030F Value ($ Million)

    15.4. Eastern Europe Filgrastim Biosimilars Market, Segmentation By Application, Historic And Forecast, 2015 – 2019, 2023F, 2025F, 2030F, Value ($ Million)

    15.5. Eastern Europe Filgrastim Biosimilars Market, Segmentation By Distribution Channel, Historic And Forecast, 2015 – 2019, 2023F, 2025F, 2030F, Value ($ Million)

    15.6. Eastern Europe Filgrastim Biosimilars Market: Country Analysis

    15.7. Russia Filgrastim Biosimilars Market

    15.8. Russia Filgrastim Biosimilars Market, Historic Market Growth, 2015 – 2019, Value ($ Million)

    15.9. Russia Filgrastim Biosimilars Market, Forecast Market Growth, 2019 – 2023, 2025F, 2030F Value ($ Million)

    15.10. Russia Filgrastim Biosimilars Market, Segmentation By Application, Historic And Forecast, 2015 – 2019, 2023F, 2025F, 2030F, Value ($ Million)

    15.11. Russia Filgrastim Biosimilars Market, Segmentation By Distribution Channel, Historic And Forecast, 2015 – 2019, 2023F, 2025F, 2030F, Value ($ Million)

    16. North America Filgrastim Biosimilars Market

    16.1. North America Filgrastim Biosimilars Market Overview

    16.1.1. Region Information

    16.1.2. Impact Of COVID-19

    16.1.3. Market Information

    16.1.4. Background Information

    16.1.5. Government Initiatives

    16.1.6. Regulations

    16.1.7. Regulatory Bodies

    16.1.8. Major Associations

    16.1.9. Taxes Levied

    16.1.10. Corporate Tax Structure

    16.1.11. Investments

    16.1.12. Major Companies

    16.2. North America Filgrastim Biosimilars Market, Historic Market Growth, 2015 – 2019, Value ($ Million)

    16.3. North America Filgrastim Biosimilars Market, Forecast Market Growth, 2019 – 2023, 2025F, 2030F Value ($ Million)

    16.4. North America Filgrastim Biosimilars Market, Segmentation By Application, Historic And Forecast, 2015 – 2019, 2023F, 2025F, 2030F, Value ($ Million)

    16.5. North America Filgrastim Biosimilars Market, Segmentation By Distribution Channel, Historic And Forecast, 2015 – 2019, 2023F, 2025F, 2030F, Value ($ Million)

    16.6. North America Filgrastim Biosimilars Market: Country Analysis

    16.7. USA Filgrastim Biosimilars Market

    16.8. USA Filgrastim Biosimilars Market Overview

    16.8.1. Country Information

    16.8.2. Impact Of COVID-19

    16.8.3. Market Information

    16.8.4. Background Information

    16.8.5. Government Initiatives

    16.8.6. Regulations

    16.8.7. Regulatory Bodies

    16.8.8. Major Associations

    16.8.9. Taxes Levied

    16.8.10. Corporate Tax Structure

    16.8.11. Investments

    16.8.12. Major Companies

    16.9. USA Filgrastim Biosimilars Market, Historic Market Growth, 2015 – 2019, Value ($ Million)

    16.10. USA Filgrastim Biosimilars Market, Forecast Market Growth, 2019 – 2023, 2025F, 2030F Value ($ Million)

    16.11. USA Filgrastim Biosimilars Market, Segmentation By Application, Historic And Forecast, 2015 – 2019, 2023F, 2025F, 2030F, Value ($ Million)

    16.12. USA Filgrastim Biosimilars Market, Segmentation By Distribution Channel, Historic And Forecast, 2015 – 2019, 2023F, 2025F, 2030F, Value ($ Million)

    17. South America Filgrastim Biosimilars Market

    17.1. South America Filgrastim Biosimilars Market Overview

    17.1.1. Region Information

    17.1.2. Impact Of COVID-19

    17.1.3. Market Information

    17.1.4. Background Information

    17.1.5. Government Initiatives

    17.1.6. Regulations

    17.1.7. Regulatory Bodies

    17.1.8. Major Associations

    17.1.9. Taxes Levied

    17.1.10. Corporate Tax Structure

    17.1.11. Major Companies

    17.2. South America Filgrastim Biosimilars Market, Historic Market Growth, 2015 – 2019, Value ($ Million)

    17.3. South America Filgrastim Biosimilars Market, Forecast Market Growth, 2019 – 2023, 2025F, 2030F Value ($ Million)

    17.4. South America Filgrastim Biosimilars Market, Segmentation By Application, Historic And Forecast, 2015 – 2019, 2023F, 2025F, 2030F, Value ($ Million)

    17.5. South America Filgrastim Biosimilars Market, Segmentation By Distribution Channel, Historic And Forecast, 2015 – 2019, 2023F, 2025F, 2030F, Value ($ Million)

    17.6. South America Filgrastim Biosimilars Market: Country Analysis

    17.7. Brazil Filgrastim Biosimilars Market

    17.8. Brazil Filgrastim Biosimilars Market, Historic Market Growth, 2015 – 2019, Value ($ Million)

    17.9. Brazil Filgrastim Biosimilars Market, Forecast Market Growth, 2019 – 2023, 2025F, 2030F Value ($ Million)

    17.10. Brazil Filgrastim Biosimilars Market, Segmentation By Application, Historic And Forecast, 2015 – 2019, 2023F, 2025F, 2030F, Value ($ Million)

    17.11. Brazil Filgrastim Biosimilars Market, Segmentation By Distribution Channel, Historic And Forecast, 2015 – 2019, 2023F, 2025F, 2030F, Value ($ Million)

    18. Middle East Filgrastim Biosimilars Market

    18.1. Middle East Filgrastim Biosimilars Market Overview

    18.1.1. Region Information

    18.1.2. Impact Of COVID-19

    18.1.3. Market Information

    18.1.4. Background Information

    18.1.5. Government Initiatives

    18.1.6. Regulations

    18.1.7. Regulatory Bodies

    18.1.8. Major Associations

    18.1.9. Taxes Levied

    18.1.10. Corporate Tax Structure

    18.1.11. Investments

    18.1.12. Major Companies

    18.2. Middle East Filgrastim Biosimilars Market, Historic Market Growth, 2015 – 2019, Value ($ Million)

    18.3. Middle East Filgrastim Biosimilars Market, Forecast Market Growth, 2019 – 2023, 2025F, 2030F Value ($ Million)

    18.4. Middle East Filgrastim Biosimilars Market, Segmentation By Application, Historic And Forecast, 2015 – 2019, 2023F, 2025F, 2030F, Value ($ Million)

    18.5. Middle East Filgrastim Biosimilars Market, Segmentation By Distribution Channel, Historic And Forecast, 2015 – 2019, 2023F, 2025F, 2030F, Value ($ Million)

    19. Africa Filgrastim Biosimilars Market

    19.1. Africa Filgrastim Biosimilars Market Overview

    19.1.1. Region Information

    19.1.2. Impact Of COVID-19

    19.1.3. Market Information

    19.1.4. Background Information

    19.1.5. Government Initiatives

    19.1.6. Regulations

    19.1.7. Regulatory Bodies

    19.1.8. Major Associations

    19.1.9. Taxes Levied

    19.1.10. Corporate Tax Structure

    19.1.11. Major Companies

    19.2. Africa Filgrastim Biosimilars Market, Historic Market Growth, 2015 – 2019, Value ($ Million)

    19.3. Africa Filgrastim Biosimilars Market, Forecast Market Growth, 2019 – 2023, 2025F, 2030F Value ($ Million)

    19.4. Africa Filgrastim Biosimilars Market, Segmentation By Application, Historic And Forecast, 2015 – 2019, 2023F, 2025F, 2030F, Value ($ Million)

    19.5. Africa Filgrastim Biosimilars Market, Segmentation By Distribution Channel, Historic And Forecast, 2015 – 2019, 2023F, 2025F, 2030F, Value ($ Million)

    20. Global Filgrastim Biosimilars Market Competitive Landscape

    20.1. Company Profiles

    20.2. Teva Pharmaceutical Industries Ltd.

    20.2.1. Company Overview

    20.2.2. Products And Services

    20.2.3. Business Strategy

    20.2.4. Financial Overview

    20.3. Novartis International AG

    20.3.1. Company Overview

    20.3.2. Products And Services

    20.3.3. Business Strategy

    20.3.4. Financial Overview

    20.4. Biocon Limited

    20.4.1. Company Overview

    20.4.2. Products And Services

    20.4.3. Business Strategy

    20.4.4. Financial Overview

    20.5. Intas Biopharmaceuticals

    20.5.1. Company Overview

    20.5.2. Products And Services

    20.5.3. Business Strategy

    20.5.4. Financial Overview

    20.6. Dr. Reddy`s Laboratories

    20.6.1. Company Overview

    20.6.2. Products And Services

    20.6.3. Business Strategy

    20.6.4. Financial Overview

    21. Key Mergers And Acquisitions In The Filgrastim Biosimilars Market

    21.1. Biocon Biologics Signs Licensing Agreement With Evotec

    21.2. Samsung Bioepis Enters Into An Agreement With C-Bridge Capital

    21.3. Kashiv Pharma Acquired Adello Biologics

    21.4. Amneal Pharmaceuticals Merge With Impax Laboratories

    21.5. Biocon Merged With Sandoz

    22. Filgrastim Biosimilars Market Opportunities And Strategies

    22.1. Global Filgrastim Biosimilars Market In 2023 – Countries Offering Most New Opportunities

    22.2. Global Filgrastim Biosimilars Market In 2023 – Segments Offering Most New Opportunities

    22.3. Global Filgrastim Biosimilars Market In 2023 – Growth Strategies

    22.3.1. Market Trend Based Strategies

    22.3.2. Competitor Strategies

    23. Filgrastim Biosimilars Market, Conclusions And Recommendations

    23.1. Conclusions

    23.2. Recommendations

    23.2.1. Product

    23.2.2. Place

    23.2.3. Price

    23.2.4. Promotion

    23.2.5. People

    24. Appendix

    24.1. Market Data Sources

    24.2. Research Methodology

    24.3. Currencies

    24.4. Research Inquiries

    24.5. The Business Research Company

    24.6. Copyright and Disclaimer

List Of Tables

    Table 1: Global Filgrastim Biosimilars Market, Historic, 2015 – 2019, $ Million
  • Table 2: Global Filgrastim Biosimilars Market, Forecast, 2019 – 2023, 2025F, 2030F, $ Million
  • Table 3: Global Filgrastim Biosimilars Market, Segmentation By Application, Historic And Forecast, 2015 – 2019, 2023F, 2025F, 2030F, %
  • Table 4: Global Filgrastim Biosimilars Market, Segmentation By Application, Historic And Forecast, 2015 – 2019, 2023F, 2025F, 2030F, $ Million
  • Table 5: Global Filgrastim Biosimilars Market, Segmentation By Distribution Channel, Historic And Forecast, 2015 – 2019, 2023F, 2025F, 2030F, %
  • Table 6: Global Filgrastim Biosimilars Market, Segmentation By Distribution Channel, Historic And Forecast, 2015 – 2019, 2023F, 2025F, 2030F, $ Million
  • Table 7: Global Filgrastim Biosimilars Market, By Region, Historic and Forecast, 2015 – 2019, 2023F, 2025F, 2030F, %
  • Table 8: Global Filgrastim Biosimilars Market, By Region, Historic and Forecast, 2015 – 2019, 2023F, 2025F, 2030F, $ Million
  • Table 9: Global Filgrastim Biosimilars Market, By Country, Historic and Forecast, 2015 – 2019, 2023F, 2025F, 2030F, %
  • Table 10: Global Filgrastim Biosimilars Market, By Country, Historic and Forecast, 2015 – 2019, 2023F, 2025F, 2030F, $ Million
  • Table 11: Asia Pacific Cancer Prevalence, Estimated Average Expenditure, 2019, $
  • Table 12: Asia-Pacific Per Capita Healthcare Expenditure, 2015-2019, $
  • Table 13: Asia-Pacific Per Capita Net Disposable Income, 2015-2019, $
  • Table 14:  Asia Pacific Population By Age Group, 2015-2023, Thousands
  • Table 15: Asia-Pacific Biologics Market Size, 2015-2019, $ Billion
  • Table 16: Asia-Pacific Filgrastim Biosimilars Market, Historic, 2015 – 2019, $ Million
  • Table 17: Asia-Pacific Filgrastim Biosimilars Market, Forecast, 2019 – 2023, 2025F, 2030F, $ Million
  • Table 18: Asia-Pacific Filgrastim Biosimilars Market, Segmentation By Application, Historic And Forecast, 2015 – 2019, 2023F, 2025F, 2030F, %
  • Table 19: Asia-Pacific Filgrastim Biosimilars Market, Segmentation By Application, Historic And Forecast, 2015 – 2019, 2023F, 2025F, 2030F, $ Million
  • Table 20: Asia-Pacific Filgrastim Biosimilars Market, Segmentation By Distribution Channel, Historic And Forecast, 2015 – 2019, 2023F, 2025F, 2030F, %
  • Table 21: Asia-Pacific Filgrastim Biosimilars Market, Segmentation By Distribution Channel, Historic And Forecast, 2015 – 2019, 2023F, 2025F, 2030F, $ Million
  • Table 22: China Cancer Prevalence, Estimated Average Expenditure, 2019, $
  • Table 23: China Per Capita Healthcare Expenditure, 2015-2019, $
  • Table 24: China Per Capita Net Disposable Income, 2015-2019, $
  • Table 25:  China Population By Age Group, 2015-2023, Thousands
  • Table 26: China Biologics Market Size, 2015-2019, $ Billion
  • Table 27: China Filgrastim Biosimilars Market, Historic, 2015 – 2019, $ Million
  • Table 28: China Filgrastim Biosimilars Market, Forecast, 2019 – 2023, 2025F, 2030F, $ Million
  • Table 29: China Filgrastim Biosimilars Market, Segmentation By Application, Historic And Forecast, 2015 – 2019, 2023F, 2025F, 2030F, %
  • Table 30: China Filgrastim Biosimilars Market, Segmentation By Application, Historic And Forecast, 2015 – 2019, 2023F, 2025F, 2030F, $ Million
  • Table 31: China Filgrastim Biosimilars Market, Segmentation By Distribution Channel, Historic And Forecast, 2015 – 2019, 2023F, 2025F, 2030F, %
  • Table 32: China Filgrastim Biosimilars Market, Segmentation By Distribution Channel, Historic And Forecast, 2015 – 2019, 2023F, 2025F, 2030F, $ Million
  • Table 33: India Cancer Prevalence, Estimated Average Expenditure, 2019, $
  • Table 34: India Per Capita Healthcare Expenditure, 2015-2019, $
  • Table 35: India Per Capita Net Disposable Income, 2015-2019, $
  • Table 36:  India Population By Age Group, 2015-2023, Thousands
  • Table 37: India Biologics Market Size, 2015-2019, $ Billion
  • Table 38: India Filgrastim Biosimilars Market, Historic, 2015 – 2019, $ Million
  • Table 39: India Filgrastim Biosimilars Market, Forecast, 2019 – 2023, 2025F, 2030F, $ Million
  • Table 40: India Filgrastim Biosimilars Market, Segmentation By Application, Historic And Forecast, 2015 – 2019, 2023F, 2025F, 2030F, %
  • Table 41: India Filgrastim Biosimilars Market, Segmentation By Application, Historic And Forecast, 2015 – 2019, 2023F, 2025F, 2030F, $ Million
  • Table 42: India Filgrastim Biosimilars Market, Segmentation By Distribution Channel, Historic And Forecast, 2015 – 2019, 2023F, 2025F, 2030F, %
  • Table 43: India Filgrastim Biosimilars Market, Segmentation By Distribution Channel, Historic And Forecast, 2015 – 2019, 2023F, 2025F, 2030F, $ Million
  • Table 44: Japan Cancer Prevalence, Estimated Average Expenditure, 2019, $
  • Table 45: Japan Per Capita Healthcare Expenditure, 2015-2019, $
  • Table 46: Japan Per Capita Net Disposable Income, 2015-2019, $
  • Table 47:  Japan Population By Age Group, 2015-2023, Thousands
  • Table 48: Japan Biologics Market Size, 2015-2019, $ Billion
  • Table 49: Japan Filgrastim Biosimilars Market, Historic, 2015 – 2019, $ Million
  • Table 50: Japan Filgrastim Biosimilars Market, Forecast, 2019 – 2023, 2025F, 2030F, $ Million
  • Table 51: Japan Filgrastim Biosimilars Market, Segmentation By Application, Historic And Forecast, 2015 – 2019, 2023F, 2025F, 2030F, %
  • Table 52: Japan Filgrastim Biosimilars Market, Segmentation By Application, Historic And Forecast, 2015 – 2019, 2023F, 2025F, 2030F, $ Million
  • Table 53: Japan Filgrastim Biosimilars Market, Segmentation By Distribution Channel, Historic And Forecast, 2015 – 2019, 2023F, 2025F, 2030F, %
  • Table 54: Japan Filgrastim Biosimilars Market, Segmentation By Distribution Channel, Historic And Forecast, 2015 – 2019, 2023F, 2025F, 2030F, $ Million
  • Table 55: Australia Filgrastim Biosimilars Market, Historic, 2015 – 2019, $ Million
  • Table 56: Australia Filgrastim Biosimilars Market, Forecast, 2019 – 2023, 2025F, 2030F, $ Million
  • Table 57: Australia Filgrastim Biosimilars Market, Segmentation By Application, Historic And Forecast, 2015 – 2019, 2023F, 2025F, 2030F, %
  • Table 58: Australia Filgrastim Biosimilars Market, Segmentation By Application, Historic And Forecast, 2015 – 2019, 2023F, 2025F, 2030F, $ Million
  • Table 59: Australia Filgrastim Biosimilars Market, Segmentation By Distribution Channel, Historic And Forecast, 2015 – 2019, 2023F, 2025F, 2030F, %
  • Table 60: Australia Filgrastim Biosimilars Market, Segmentation By Distribution Channel, Historic And Forecast, 2015 – 2019, 2023F, 2025F, 2030F, $ Million
  • Table 61: Indonesia Filgrastim Biosimilars Market, Historic, 2015 – 2019, $ Million
  • Table 62: Indonesia Filgrastim Biosimilars Market, Forecast, 2019 – 2023, 2025F, 2030F, $ Million
  • Table 63: Indonesia Filgrastim Biosimilars Market, Segmentation By Application, Historic And Forecast, 2015 – 2019, 2023F, 2025F, 2030F, %
  • Table 64: Indonesia Filgrastim Biosimilars Market, Segmentation By Application, Historic And Forecast, 2015 – 2019, 2023F, 2025F, 2030F, $ Million
  • Table 65: Indonesia Filgrastim Biosimilars Market, Segmentation By Distribution Channel, Historic And Forecast, 2015 – 2019, 2023F, 2025F, 2030F, %
  • Table 66: Indonesia Filgrastim Biosimilars Market, Segmentation By Distribution Channel, Historic And Forecast, 2015 – 2019, 2023F, 2025F, 2030F, $ Million
  • Table 67: South Korea Filgrastim Biosimilars Market, Historic, 2015 – 2019, $ Million
  • Table 68: South Korea Filgrastim Biosimilars Market, Forecast, 2019 – 2023, 2025F, 2030F, $ Million
  • Table 69: South Korea Filgrastim Biosimilars Market, Segmentation By Application, Historic And Forecast, 2015 – 2019, 2023F, 2025F, 2030F, %
  • Table 70: South Korea Filgrastim Biosimilars Market, Segmentation By Application, Historic And Forecast, 2015 – 2019, 2023F, 2025F, 2030F, $ Million
  • Table 71: South Korea Filgrastim Biosimilars Market, Segmentation By Distribution Channel, Historic And Forecast, 2015 – 2019, 2023F, 2025F, 2030F, %
  • Table 72: South Korea Filgrastim Biosimilars Market, Segmentation By Distribution Channel, Historic And Forecast, 2015 – 2019, 2023F, 2025F, 2030F, $ Million
  • Table 73: Western Europe Estimated Average Expenditure, Cancer Prevalence, 2019
  • Table 74: Western Europe Per Capita Healthcare Expenditure, 2015-2019, $
  • Table 75: Western Europe Per Capita Net Disposable Income, 2015-2019, $
  • Table 76:  Western Europe Population By Age Group, 2015-2023, Thousands
  • Table 77: Western Europe Biologics Market Size, 2015-2019, $ Billion
  • Table 78: Western Europe Filgrastim Biosimilars Market, Historic, 2015 – 2019, $ Million
  • Table 79: Western Europe Filgrastim Biosimilars Market, Forecast, 2019 – 2023, 2025F, 2030F, $ Million
  • Table 80: Western Europe Filgrastim Biosimilars Market, Segmentation By Application, Historic And Forecast, 2015 – 2019, 2023F, 2025F, 2030F, %
  • Table 81: Western Europe Filgrastim Biosimilars Market, Segmentation By Application, Historic And Forecast, 2015 – 2019, 2023F, 2025F, 2030F, $ Million
  • Table 82: Western Europe Filgrastim Biosimilars Market, Segmentation By Distribution Channel, Historic And Forecast, 2015 – 2019, 2023F, 2025F, 2030F, %
  • Table 83: Western Europe Filgrastim Biosimilars Market, Segmentation By Distribution Channel, Historic And Forecast, 2015 – 2019, 2023F, 2025F, 2030F, $ Million
  • Table 84: UK Estimated Average Expenditure, Filgrastim Biosimilar Market, Cancer Prevalence, 2019
  • Table 85: UK Per Capita Healthcare Expenditure, 2015-2019, $
  • Table 86: UK Per Capita Net Disposable Income, 2015-2019, $
  • Table 87:  UK Population By Age Group, 2015-2023, Thousands
  • Table 88: UK Biologics Market Size, 2015-2019, $ Billion
  • Table 89: UK Filgrastim Biosimilars Market, Historic, 2015 – 2019, $ Million
  • Table 90: UK Filgrastim Biosimilars Market, Forecast, 2019 – 2023, 2025F, 2030F, $ Million
  • Table 91: UK Filgrastim Biosimilars Market, Segmentation By Application, Historic And Forecast, 2015 – 2019, 2023F, 2025F, 2030F, %
  • Table 92: UK Filgrastim Biosimilars Market, Segmentation By Application, Historic And Forecast, 2015 – 2019, 2023F, 2025F, 2030F, $ Million
  • Table 93: UK Filgrastim Biosimilars Market, Segmentation By Distribution Channel, Historic And Forecast, 2015 – 2019, 2023F, 2025F, 2030F, %
  • Table 94: UK Filgrastim Biosimilars Market, Segmentation By Distribution Channel, Historic And Forecast, 2015 – 2019, 2023F, 2025F, 2030F, $ Million
  • Table 95: Germany Filgrastim Biosimilars Market, Historic, 2015 – 2019, $ Million
  • Table 96: Germany Filgrastim Biosimilars Market, Forecast, 2019 – 2023, 2025F, 2030F, $ Million
  • Table 97: Germany Filgrastim Biosimilars Market, Segmentation By Application, Historic And Forecast, 2015 – 2019, 2023F, 2025F, 2030F, %
  • Table 98: Germany Filgrastim Biosimilars Market, Segmentation By Application, Historic And Forecast, 2015 – 2019, 2023F, 2025F, 2030F, $ Million
  • Table 99: Germany Filgrastim Biosimilars Market, Segmentation By Distribution Channel, Historic And Forecast, 2015 – 2019, 2023F, 2025F, 2030F, %
  • Table 100: Germany Filgrastim Biosimilars Market, Segmentation By Distribution Channel, Historic And Forecast, 2015 – 2019, 2023F, 2025F, 2030F, $ Million
  • Table 101: France Filgrastim Biosimilars Market, Historic, 2015 – 2019, $ Million
  • Table 102: France Filgrastim Biosimilars Market, Forecast, 2019 – 2023, 2025F, 2030F, $ Million
  • Table 103: France Filgrastim Biosimilars Market, Segmentation By Application, Historic And Forecast, 2015 – 2019, 2023F, 2025F, 2030F, %
  • Table 104: France Filgrastim Biosimilars Market, Segmentation By Application, Historic And Forecast, 2015 – 2019, 2023F, 2025F, 2030F, $ Million
  • Table 105: France Filgrastim Biosimilars Market, Segmentation By Distribution Channel, Historic And Forecast, 2015 – 2019, 2023F, 2025F, 2030F, %
  • Table 106: France Filgrastim Biosimilars Market, Segmentation By Distribution Channel, Historic And Forecast, 2015 – 2019, 2023F, 2025F, 2030F, $ Million
  • Table 107: Eastern Europe Estimated Average Expenditure, Filgrastim Biosimilar Market, Cancer Prevalence, 2019
  • Table 108: Eastern Europe Per Capita Healthcare Expenditure, 2015-2019, $
  • Table 109:  Eastern Europe Population By Age Group, 2015-2023, Thousands
  • Table 110: Eastern Europe Per Capita Net Disposable Income, 2015-2019, $
  • Table 111: Eastern Europe Biologics Market Size, 2015-2019, $ Billion
  • Table 112: Eastern Europe Filgrastim Biosimilars Market, Historic, 2015 – 2019, $ Million
  • Table 113: Eastern Europe Filgrastim Biosimilars Market, Forecast, 2019 – 2023, 2025F, 2030F, $ Million
  • Table 114: Eastern Europe Filgrastim Biosimilars Market, Segmentation By Application, Historic And Forecast, 2015 – 2019, 2023F, 2025F, 2030F, %
  • Table 115: Eastern Europe Filgrastim Biosimilars Market, Segmentation By Application, Historic And Forecast, 2015 – 2019, 2023F, 2025F, 2030F, $ Million
  • Table 116: Eastern Europe Filgrastim Biosimilars Market, Segmentation By Distribution Channel, Historic And Forecast, 2015 – 2019, 2023F, 2025F, 2030F, %
  • Table 117: Eastern Europe Filgrastim Biosimilars Market, Segmentation By Distribution Channel, Historic And Forecast, 2015 – 2019, 2023F, 2025F, 2030F, $ Million
  • Table 118: Russia Filgrastim Biosimilars Market, Historic, 2015 – 2019, $ Million
  • Table 119: Russia Filgrastim Biosimilars Market, Forecast, 2019 – 2023, 2025F, 2030F, $ Million
  • Table 120: Russia Filgrastim Biosimilars Market, Segmentation By Application, Historic And Forecast, 2015 – 2019, 2023F, 2025F, 2030F, %
  • Table 121: Russia Filgrastim Biosimilars Market, Segmentation By Application, Historic And Forecast, 2015 – 2019, 2023F, 2025F, 2030F, $ Million
  • Table 122: Russia Filgrastim Biosimilars Market, Segmentation By Distribution Channel, Historic And Forecast, 2015 – 2019, 2023F, 2025F, 2030F, %
  • Table 123: Russia Filgrastim Biosimilars Market, Segmentation By Distribution Channel, Historic And Forecast, 2015 – 2019, 2023F, 2025F, 2030F, $ Million
  • Table 124: North America Estimated Average Expenditure, Filgrastim Biosimilar Market, Cancer Prevalence, 2019
  • Table 125: North America Per Capita Healthcare Expenditure, 2015-2019, $
  • Table 126: North America Per Capita Net Disposable Income, 2015-2019, $
  • Table 127:  North America Population By Age Group, 2015-2023, Thousands
  • Table 128: North America Biologics Market Size, 2015-2019, $ Billion
  • Table 129: North America Filgrastim Biosimilars Market, Historic, 2015 – 2019, $ Million
  • Table 130: North America Filgrastim Biosimilars Market, Forecast, 2019 – 2023, 2025F, 2030F, $ Million
  • Table 131: North America Filgrastim Biosimilars Market, Segmentation By Application, Historic And Forecast, 2015 – 2019, 2023F, 2025F, 2030F, %
  • Table 132: North America Filgrastim Biosimilars Market, Segmentation By Application, Historic And Forecast, 2015 – 2019, 2023F, 2025F, 2030F, $ Million
  • Table 133: North America Filgrastim Biosimilars Market, Segmentation By Distribution Channel, Historic And Forecast, 2015 – 2019, 2023F, 2025F, 2030F, %
  • Table 134: North America Filgrastim Biosimilars Market, Segmentation By Distribution Channel, Historic And Forecast, 2015 – 2019, 2023F, 2025F, 2030F, $ Million
  • Table 135: USA Estimated Average Expenditure, Filgrastim Biosimilar Market, Cancer Prevalence, 2019
  • Table 136: USA Per Capita Healthcare Expenditure, 2015-2019, $
  • Table 137: USA Per Capita Net Disposable Income, 2015-2019, $
  • Table 138:  USA Market, Population By Age Group, 2015-2023, Thousands
  • Table 139: USA Biologics Market Size, 2015-2019, $ Billion
  • Table 140: USA Filgrastim Biosimilars Market, Historic, 2015 – 2019, $ Million
  • Table 141: USA Filgrastim Biosimilars Market, Forecast, 2019 – 2023, 2025F, 2030F, $ Million
  • Table 142: USA Filgrastim Biosimilars Market, Segmentation By Application, Historic And Forecast, 2015 – 2019, 2023F, 2025F, 2030F, %
  • Table 143: USA Filgrastim Biosimilars Market, Segmentation By Application, Historic And Forecast, 2015 – 2019, 2023F, 2025F, 2030F, $ Million
  • Table 144: USA Filgrastim Biosimilars Market, Segmentation By Distribution Channel, Historic And Forecast, 2015 – 2019, 2023F, 2025F, 2030F, %
  • Table 145: USA Filgrastim Biosimilars Market, Segmentation By Distribution Channel, Historic And Forecast, 2015 – 2019, 2023F, 2025F, 2030F, $ Million
  • Table 146: South America Estimated Average Expenditure, Filgrastim Biosimilar Market, Cancer Prevalence, 2019
  • Table 147: South America Per Capita Healthcare Expenditure, 2015-2019, $
  • Table 148:  South America Population By Age Group, 2015-2023, Thousands
  • Table 149: South America Per Capita Net Disposable Income, 2015-2019, $
  • Table 150: South America Biologics Market Size, 2015-2019, $ Billion
  • Table 151: South America Filgrastim Biosimilars Market, Historic, 2015 – 2019, $ Million
  • Table 152: South America Filgrastim Biosimilars Market, Forecast, 2019 – 2023, 2025F, 2030F, $ Million
  • Table 153: South America Filgrastim Biosimilars Market, Segmentation By Application, Historic And Forecast, 2015 – 2019, 2023F, 2025F, 2030F, %
  • Table 154: South America Filgrastim Biosimilars Market, Segmentation By Application, Historic And Forecast, 2015 – 2019, 2023F, 2025F, 2030F, $ Million
  • Table 155: South America Filgrastim Biosimilars Market, Segmentation By Distribution Channel, Historic And Forecast, 2015 – 2019, 2023F, 2025F, 2030F, %
  • Table 156: South America Filgrastim Biosimilars Market, Segmentation By Distribution Channel, Historic And Forecast, 2015 – 2019, 2023F, 2025F, 2030F, $ Million
  • Table 157: Brazil Filgrastim Biosimilars Market, Historic, 2015 – 2019, $ Million
  • Table 158: Brazil Filgrastim Biosimilars Market, Forecast, 2019 – 2023, 2025F, 2030F, $ Million
  • Table 159: Brazil Filgrastim Biosimilars Market, Segmentation By Application, Historic And Forecast, 2015 – 2019, 2023F, 2025F, 2030F, %
  • Table 160: Brazil Filgrastim Biosimilars Market, Segmentation By Application, Historic And Forecast, 2015 – 2019, 2023F, 2025F, 2030F, $ Million
  • Table 161: Brazil Filgrastim Biosimilars Market, Segmentation By Distribution Channel, Historic And Forecast, 2015 – 2019, 2023F, 2025F, 2030F, %
  • Table 162: Brazil Filgrastim Biosimilars Market, Segmentation By Distribution Channel, Historic And Forecast, 2015 – 2019, 2023F, 2025F, 2030F, $ Million
  • Table 163: Middle East Per Capita Healthcare Expenditure, 2015-2019, $
  • Table 164: Middle East Per Capita Net Disposable Income, 2015-2019, $
  • Table 165:  Middle East Population By Age Group, 2015-2023, Thousands
  • Table 166: Middle East Biologics Market Size, 2015-2019, $ Billion
  • Table 167: Middle East Filgrastim Biosimilars Market, Historic, 2015 – 2019, $ Million
  • Table 168: Middle East Filgrastim Biosimilars Market, Forecast, 2019 – 2023, 2025F, 2030F, $ Million
  • Table 169: Middle East Filgrastim Biosimilars Market, Segmentation By Application, Historic And Forecast, 2015 – 2019, 2023F, 2025F, 2030F, %
  • Table 170: Middle East Filgrastim Biosimilars Market, Segmentation By Application, Historic And Forecast, 2015 – 2019, 2023F, 2025F, 2030F, $ Million
  • Table 171: Middle East Filgrastim Biosimilars Market, Segmentation By Distribution Channel, Historic And Forecast, 2015 – 2019, 2023F, 2025F, 2030F, %
  • Table 172: Middle East Filgrastim Biosimilars Market, Segmentation By Distribution Channel, Historic And Forecast, 2015 – 2019, 2023F, 2025F, 2030F, $ Million
  • Table 173: Africa Per Capita Healthcare Expenditure, 2015-2019, $
  • Table 174: Africa Per Capita Net Disposable Income, 2015-2019, $
  • Table 175:  Africa Population By Age Group, 2015-2023, Thousands
  • Table 176: Africa Biologics Market Size, 2015-2019, $ Billion
  • Table 177: Africa Filgrastim Biosimilars Market, Historic, 2015 – 2019, $ Million
  • Table 178: Africa Filgrastim Biosimilars Market, Forecast, 2019 – 2023, 2025F, 2030F, $ Million
  • Table 179: Africa Filgrastim Biosimilars Market, Segmentation By Application, Historic And Forecast, 2015 – 2019, 2023F, 2025F, 2030F, %
  • Table 180: Africa Filgrastim Biosimilars Market, Segmentation By Application, Historic And Forecast, 2015 – 2019, 2023F, 2025F, 2030F, $ Million
  • Table 181: Africa Filgrastim Biosimilars Market, Segmentation By Distribution Channel, Historic And Forecast, 2015 – 2019, 2023F, 2025F, 2030F, %
  • Table 182: Africa Filgrastim Biosimilars Market, Segmentation By Distribution Channel, Historic And Forecast, 2015 – 2019, 2023F, 2025F, 2030F, $ Million
  • Table 183: Global Filgrastim Biosimilars Market, Key Competitor Estimated Market Shares, 2019, Percentage (%)
  • Table 184: Teva Pharmaceutical Industries Ltd.– Financial Performance, 2015 - 2019, $ Billion
  • Table 185: Novartis International AG – Financial Performance, 2015 - 2019, $ Billion
  • Table 186: Biocon Limited – Financial Performance, 2015 - 2019, $ Billion
  • Table  187: Dr. Reddy`s Laboratories – Financial Performance, 2015 - 2019, $ Billion
  • Table 188: Global Filgrastim Biosimilars Market Size Gain ($ Million), 2019 – 2023, By Country
  • Table 189: Global Filgrastim Biosimilars Market Size Gain ($ Million), Segmentation By Application, 2019 – 2023
  • Table 190: Global Filgrastim Biosimilars Market Size Gain ($ Million), Segmentation By Distribution Channel, 2019 – 2023
  • Table 191: Filgrastim Biosimilars Market Data Sources

List Of Figures

    Figure 1: Global Filgrastim Biosimilars Market Segmentation By Application
  • Figure 2: Global Filgrastim Biosimilars Market Segmentation By Distribution Channel
  • Figure 3: Global Filgrastim Biosimilars Market, Historic, 2015 – 2019, $ Million
  • Figure 4: Global Filgrastim Biosimilars Market, Forecast, 2019 – 2023, 2025F, 2030F, $ Million
  • Figure 5: Global Filgrastim Biosimilars Market, Segmentation By Application, Historic And Forecast, 2015 – 2019, 2023F, 2025F, 2030F, %
  • Figure 6: Global Filgrastim Biosimilars Market, Segmentation By Distribution Channel, Historic And Forecast, 2015 – 2019, 2023F, 2025F, 2030F, %
  • Figure 7: Global Filgrastim Biosimilars Market, By Region, Historic and Forecast, 2015 – 2019, 2023F, 2025F, 2030F, %
  • Figure 8: Global Filgrastim Biosimilars Market, By Country, Historic and Forecast, 2015 – 2019, 2023F, 2025F, 2030F, %
  • Figure 9: Asia-Pacific Filgrastim Biosimilars Market, Historic, 2015 – 2019, $ Million
  • Figure 10: Asia-Pacific Filgrastim Biosimilars Market, Forecast, 2019 – 2023, 2025F, 2030F, $ Million
  • Figure 11: Asia-Pacific Filgrastim Biosimilars Market, Segmentation By Application, Historic And Forecast, 2015 – 2019, 2023F, 2025F, 2030F, %
  • Figure 12: Asia-Pacific Filgrastim Biosimilars Market, Segmentation By Distribution Channel, Historic And Forecast, 2015 – 2019, 2023F, 2025F, 2030F, %
  • Figure 13: China Filgrastim Biosimilars Market, Historic, 2015 – 2019, $ Million
  • Figure 14: China Filgrastim Biosimilars Market, Forecast, 2019 – 2023, 2025F, 2030F, $ Million
  • Figure 15: China Filgrastim Biosimilars Market, Segmentation By Application, Historic And Forecast, 2015 – 2019, 2023F, 2025F, 2030F, %
  • Figure 16: China Filgrastim Biosimilars Market, Segmentation By Distribution Channel, Historic And Forecast, 2015 – 2019, 2023F, 2025F, 2030F, %
  • Figure 17: India Filgrastim Biosimilars Market, Historic, 2015 – 2019, $ Million
  • Figure 18: India Filgrastim Biosimilars Market, Forecast, 2019 – 2023, 2025F, 2030F, $ Million
  • Figure 19: India Filgrastim Biosimilars Market, Segmentation By Application, Historic And Forecast, 2015 – 2019, 2023F, 2025F, 2030F, %
  • Figure 20: India Filgrastim Biosimilars Market, Segmentation By Distribution Channel, Historic And Forecast, 2015 – 2019, 2023F, 2025F, 2030F, %
  • Figure 21: Japan Filgrastim Biosimilars Market, Historic, 2015 – 2019, $ Million
  • Figure 22: Japan Filgrastim Biosimilars Market, Forecast, 2019 – 2023, 2025F, 2030F, $ Million
  • Figure 23: Japan Filgrastim Biosimilars Market, Segmentation By Application, Historic And Forecast, 2015 – 2019, 2023F, 2025F, 2030F, %
  • Figure 24: Japan Filgrastim Biosimilars Market, Segmentation By Distribution Channel, Historic And Forecast, 2015 – 2019, 2023F, 2025F, 2030F, %
  • Figure 25: Australia Filgrastim Biosimilars Market, Historic, 2015 – 2019, $ Million
  • Figure 26: Australia Filgrastim Biosimilars Market, Forecast, 2019 – 2023, 2025F, 2030F, $ Million
  • Figure 27: Australia Filgrastim Biosimilars Market, Segmentation By Application, Historic And Forecast, 2015 – 2019, 2023F, 2025F, 2030F, %
  • Figure 28: Australia Filgrastim Biosimilars Market, Segmentation By Distribution Channel, Historic And Forecast, 2015 – 2019, 2023F, 2025F, 2030F, %
  • Figure 29: Indonesia Filgrastim Biosimilars Market, Historic, 2015 – 2019, $ Million
  • Figure 30: Indonesia Filgrastim Biosimilars Market, Forecast, 2019 – 2023, 2025F, 2030F, $ Million
  • Figure 31: Indonesia Filgrastim Biosimilars Market, Segmentation By Application, Historic And Forecast, 2015 – 2019, 2023F, 2025F, 2030F, %
  • Figure 32: Indonesia Filgrastim Biosimilars Market, Segmentation By Distribution Channel, Historic And Forecast, 2015 – 2019, 2023F, 2025F, 2030F, %
  • Figure 33: South Korea Filgrastim Biosimilars Market, Historic, 2015 – 2019, $ Million
  • Figure 34: South Korea Filgrastim Biosimilars Market, Forecast, 2019 – 2023, 2025F, 2030F, $ Million
  • Figure 35: South Korea Filgrastim Biosimilars Market, Segmentation By Application, Historic And Forecast, 2015 – 2019, 2023F, 2025F, 2030F, %
  • Figure 36: South Korea Filgrastim Biosimilars Market, Segmentation By Distribution Channel, Historic And Forecast, 2015 – 2019, 2023F, 2025F, 2030F, %
  • Figure 37: Western Europe Filgrastim Biosimilars Market, Historic, 2015 – 2019, $ Million
  • Figure 38: Western Europe Filgrastim Biosimilars Market, Forecast, 2019 – 2023, 2025F, 2030F, $ Million
  • Figure 39: Western Europe Filgrastim Biosimilars Market, Segmentation By Application, Historic And Forecast, 2015 – 2019, 2023F, 2025F, 2030F, %
  • Figure 40: Western Europe Filgrastim Biosimilars Market, Segmentation By Distribution Channel, Historic And Forecast, 2015 – 2019, 2023F, 2025F, 2030F, %
  • Figure 41: UK Filgrastim Biosimilars Market, Historic, 2015 – 2019, $ Million
  • Figure 42: UK Filgrastim Biosimilars Market, Forecast, 2019 – 2023, 2025F, 2030F, $ Million
  • Figure 43: UK Filgrastim Biosimilars Market, Segmentation By Application, Historic And Forecast, 2015 – 2019, 2023F, 2025F, 2030F, %
  • Figure 44: UK Filgrastim Biosimilars Market, Segmentation By Distribution Channel, Historic And Forecast, 2015 – 2019, 2023F, 2025F, 2030F, %
  • Figure 45: Germany Filgrastim Biosimilars Market, Historic, 2015 – 2019, $ Million
  • Figure 46: Germany Filgrastim Biosimilars Market, Forecast, 2019 – 2023, 2025F, 2030F, $ Million
  • Figure 47: Germany Filgrastim Biosimilars Market, Segmentation By Application, Historic And Forecast, 2015 – 2019, 2023F, 2025F, 2030F, %
  • Figure 48: Germany Filgrastim Biosimilars Market, Segmentation By Distribution Channel, Historic And Forecast, 2015 – 2019, 2023F, 2025F, 2030F, %
  • Figure 49: France Filgrastim Biosimilars Market, Historic, 2015 – 2019, $ Million
  • Figure 50: France Filgrastim Biosimilars Market, Forecast, 2019 – 2023, 2025F, 2030F, $ Million
  • Figure 51: France Filgrastim Biosimilars Market, Segmentation By Application, Historic And Forecast, 2015 – 2019, 2023F, 2025F, 2030F, %
  • Figure 52: France Filgrastim Biosimilars Market, Segmentation By Distribution Channel, Historic And Forecast, 2015 – 2019, 2023F, 2025F, 2030F, %
  • Figure 53: Eastern Europe Filgrastim Biosimilars Market, Historic, 2015 – 2019, $ Million
  • Figure 54: Eastern Europe Filgrastim Biosimilars Market, Forecast, 2019 – 2023, 2025F, 2030F, $ Million
  • Figure 55: Eastern Europe Filgrastim Biosimilars Market, Segmentation By Application, Historic And Forecast, 2015 – 2019, 2023F, 2025F, 2030F, %
  • Figure 56: Eastern Europe Filgrastim Biosimilars Market, Segmentation By Distribution Channel, Historic And Forecast, 2015 – 2019, 2023F, 2025F, 2030F, %
  • Figure 57: Russia Filgrastim Biosimilars Market, Historic, 2015 – 2019, $ Million
  • Figure 58: Russia Filgrastim Biosimilars Market, Forecast, 2019 – 2023, 2025F, 2030F, $ Million
  • Figure 59: Russia Filgrastim Biosimilars Market, Segmentation By Application, Historic And Forecast, 2015 – 2019, 2023F, 2025F, 2030F, %
  • Figure 60: Russia Filgrastim Biosimilars Market, Segmentation By Distribution Channel, Historic And Forecast, 2015 – 2019, 2023F, 2025F, 2030F, %
  • Figure 61: North America Filgrastim Biosimilars Market, Historic, 2015 – 2019, $ Million
  • Figure 62: North America Filgrastim Biosimilars Market, Forecast, 2019 – 2023, 2025F, 2030F, $ Million
  • Figure 63: North America Filgrastim Biosimilars Market, Segmentation By Application, Historic And Forecast, 2015 – 2019, 2023F, 2025F, 2030F, %
  • Figure 64: North America Filgrastim Biosimilars Market, Segmentation By Distribution Channel, Historic And Forecast, 2015 – 2019, 2023F, 2025F, 2030F, %
  • Figure 65: USA Filgrastim Biosimilars Market, Historic, 2015 – 2019, $ Million
  • Figure 66: USA Filgrastim Biosimilars Market, Forecast, 2019 – 2023, 2025F, 2030F, $ Million
  • Figure 67: USA Filgrastim Biosimilars Market, Segmentation By Application, Historic And Forecast, 2015 – 2019, 2023F, 2025F, 2030F, %
  • Figure 68: USA Filgrastim Biosimilars Market, Segmentation By Distribution Channel, Historic And Forecast, 2015 – 2019, 2023F, 2025F, 2030F, %
  • Figure 69: South America Filgrastim Biosimilars Market, Historic, 2015 – 2019, $ Million
  • Figure 70: South America Filgrastim Biosimilars Market, Forecast, 2019 – 2023, 2025F, 2030F, $ Million
  • Figure 71: South America Filgrastim Biosimilars Market, Segmentation By Application, Historic And Forecast, 2015 – 2019, 2023F, 2025F, 2030F, %
  • Figure 72: South America Filgrastim Biosimilars Market, Segmentation By Distribution Channel, Historic And Forecast, 2015 – 2019, 2023F, 2025F, 2030F, %
  • Figure 73: Brazil Filgrastim Biosimilars Market, Historic, 2015 – 2019, $ Million
  • Figure 74: Brazil Filgrastim Biosimilars Market, Forecast, 2019 – 2023, 2025F, 2030F, $ Million
  • Figure 75: Brazil Filgrastim Biosimilars Market, Segmentation By Application, Historic And Forecast, 2015 – 2019, 2023F, 2025F, 2030F, %
  • Figure 76: Brazil Filgrastim Biosimilars Market, Segmentation By Distribution Channel, Historic And Forecast, 2015 – 2019, 2023F, 2025F, 2030F, %
  • Figure 77: Middle East Filgrastim Biosimilars Market, Historic, 2015 – 2019, $ Million
  • Figure 78: Middle East Filgrastim Biosimilars Market, Forecast, 2019 – 2023, 2025F, 2030F, $ Million
  • Figure 79: Middle East Filgrastim Biosimilars Market, Segmentation By Application, Historic And Forecast, 2015 – 2019, 2023F, 2025F, 2030F, %
  • Figure 80: Middle East Filgrastim Biosimilars Market, Segmentation By Distribution Channel, Historic And Forecast, 2015 – 2019, 2023F, 2025F, 2030F, %
  • Figure 81: Africa Filgrastim Biosimilars Market, Historic, 2015 – 2019, $ Million
  • Figure 82: Africa Filgrastim Biosimilars Market, Forecast, 2019 – 2023, 2025F, 2030F, $ Million
  • Figure 83: Africa Filgrastim Biosimilars Market, Segmentation By Application, Historic And Forecast, 2015 – 2019, 2023F, 2025F, 2030F, %
  • Figure 84: Africa Filgrastim Biosimilars Market, Segmentation By Distribution Channel, Historic And Forecast, 2015 – 2019, 2023F, 2025F, 2030F, %
  • Figure 85: Global Filgrastim Biosimilars Market, Key Competitor Estimated Market Shares, 2019, Percentage (%)
  • Figure 86: Teva Pharmaceutical Industries Ltd. – Financial Performance, 2015 - 2019, $ Billion
  • Figure 87: Novartis International AG – Financial Performance, 2015 - 2019, $ Billion
  • Figure 88: Biocon Limited – Financial Performance, 2015 - 2019, $ Billion
  • Figure 89: Dr. Reddy`s Laboratories – Financial Performance, 2015 - 2019, $ Billion
Global Lung Cancer Drugs Market Report 2021 – Opportunities And Strategies, Market Forecast And Trends
Global Kidney Cancer Drugs Market Report 2021 – Opportunities And Strategies, Market Forecast And Trends
Global Interleukin Inhibitors Market Report 2021 – Opportunities And Strategies, Market Forecast And Trends
Global Immunosuppressants Market Report 2021 – Opportunities And Strategies, Market Forecast And Trends
Global Inhalation Sedatives Market Report 2021 – Opportunities And Strategies, Market Forecast And Trends
Global Insulin Drugs Market Report 2021 – Opportunities And Strategies, Market Forecast And Trends
Global Cancer Monoclonal Antibodies Market Report 2021 – Opportunities And Strategies, Market Forecast And Trends
Global Clinical Nutrition Market Report 2021 – Opportunities And Strategies, Market Forecast And Trends
Biosimilar Therapeutic Peptides Global Market Report 2021: COVID-19 Growth And Change To 2030
View Report
Rituximab Biosimilars Global Market Report 2021: COVID-19 Growth And Change To 2030
View Report
Biosimilar Monoclonal Antibodies Global Market Report 2021: COVID-19 Growth And Change To 2030
View Report
Biosimilar Lymphocyte Modulator Global Market Report 2021: COVID-19 Growth And Change To 2030
View Report
Oncology Biosimilars Global Market Report 2021: COVID-19 Growth And Change To 2030
View Report
Trastuzumab Biosimilars Global Market Report 2021: COVID-19 Growth And Change To 2030
View Report
Biostimulants Global Market Report 2021: COVID 19 Growth And Change to 2030
View Report
Pegfilgrastim Biosimilars Market - By Application (Chemotherapy Induced Neutropenia, Transplantation, Others), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Mail Order/Online Pharmacies), And By Region, Opportunities And Strategies – Global Pegfilgrastim Biosimilars Market Forecast To 2030
View Report

Call Us

+1 3156230293

(Americas)

+44 2071930708

(Europe)

+91 8897263534

(Asia & Others)